RABBIT at a Glance
Targets | Long-term monitoring of safety and efficacy of therapy with biologics, biosimilars and JAK inhibitors in patients with rheumatoid arthritis (RA) compared to therapy with conventional, synthetic DMARDs |
| Study design | Prospective observational study |
Participating physicians | Rheumatologists in practice or special outpatient departments throughout Germany. The participation of new facilities is possible at any time! Please register via the contact form |
Inclusion criteria | Patients with confirmed RA diagnosis by the rheumatologist stating the ACR criteria of 1987, disability age >=16 years, therapy: start of a new therapy with a biologic, biosimilar or JAK inhibitor or restart of a therapy with a biologic, biosimilar or JAK inhibitor after at least a three-month therapy break or start of a therapy with a conventional DMARD after failure of at least a conventional DMARD therapy. Patients who start therapy with Remicade® have not been able to start treatment with a conventional DMARD since January 1, 2017 and patients who start a new Inflectra® therapy since January 1, 2018.03.2018 are no longer included in RABBIT. |
Data collection | Questionnaires for physician and patient at the time of inclusion (at the beginning of the new therapy), after 3 and 6 months and at 6-month intervals thereafter |
observation time | At least 5 years |
time required for the physiciant | For the base bow approx. 15-30 minutes per patient, for a follow-up sheet about 10 to 15 minutes per patient |
| Study management | Pharmacoepidemiology working group of the German Rheumatism Research Center in Berlin |
